Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a prominent player in the biopharmaceutical industry, headquartered in Osaka, Japan. Founded in 1717, the company has a rich history of innovation, focusing on the research, development, and commercialisation of novel therapeutics, particularly in oncology, immunology, and pain management. Ono Pharma is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment paradigms. The company’s commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, positioning it as a leader in the global pharmaceutical market. With a strong presence in Japan and expanding operations in North America and Europe, Ono Pharmaceutical continues to make significant strides in delivering unique and effective solutions for patients worldwide.
DitchCarbon Score
How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ono Pharmaceutical's score of 51 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ono Pharmaceutical's reported carbon emissions
In 2023, Ono Pharmaceutical Co., Ltd. reported total greenhouse gas emissions of approximately 16,700,000 kg CO2e, comprising 6,700,000 kg CO2e from Scope 1, 9,400,000 kg CO2e from Scope 2, and 6,700,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to significantly reduce its carbon footprint, committing to a 55% reduction in absolute Scope 1 and 2 emissions by FY2030 and achieving net-zero emissions by FY2050, using FY2017 as the baseline. Additionally, Ono aims to reduce its absolute Scope 3 emissions by 30% by FY2030 and 60% by FY2050. These targets align with the Science Based Targets initiative (SBTi) and reflect Ono's commitment to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ono Pharmaceutical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
